Ahmad Al-Qudimat

Mr. Ahmad Al-Qudimat

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2023 in Heliyon
Verified
Journal Article
Open access
KHAYRY AL-SHAMIKHAYRY AL-SHAMI
KHAYRY AL-SHAMI
SASajeda Awadi
Sajeda Awadi
Almu'atasim KhameesAlmu'atasim Khamees
Almu'atasim Khamees
AAAhmad Malek Alsheikh
Ahmad Malek Alsheikh
SASumaiya Al-Sharif
Sumaiya Al-Sharif
Mazhar Al ZoubiMazhar Al Zoubi
Mazhar Al Zoubi
In female mammals, the development and regulation of the reproductive system and non-reproductive system are significantly influenced by estrogens (oestrogens). In addition, lipid metabolism is another physiological role of estrogens. Estrogens act through different types of receptors to introduce signals to the target cell by affecting many estrogen response elements. Breast cancer is considered mostly a hormone-dependent disease. Approximately 70% of breast cancers express progesterone receptors and/or estrogen receptors, and they are a good marker for cancer prognosis. This review will discuss estrogen metabolism and the interaction of estrogen metabolites with breast cancer. The carcinogenic role of estrogen is discussed in light of both conventional and atypical cancers susceptible to hormones, such as prostate, endometrial, and lung cancer, as we examine how estrogen contributes to the formation and activation of breast cancer. In addition, this review will discuss other factors that can be associated with estrogen-driven breast cancer.

15 September 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Abdulqadir J. NashwanAbdulqadir J. Nashwan
Abdulqadir J. Nashwan
RVRalph C. Villar
Ralph C. Villar
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
NKNisha Kader
Nisha Kader
MAMajid Alabdulla
Majid Alabdulla
KSKalpana Singh
Kalpana Singh
There have been numerous concerns regarding the physical and mental health of nurses during the COVID-19 pandemic. Stress, sleep deprivation, anxiety, and depression potentiated nurses’ vulnerability to poor eating habits. Aims and Objectives: The purpose of this study was to explore the differences between nurses’ characteristics with COVID-19 facility designation, and sleep quality, depression, anxiety, stress, eating habits, social bonds, and quality of life. Design: A cross-sectional, comparative study. Methods: An online survey was sent using the corporation’s email to nurses working in three hospitals in Qatar from September to December 2020. One of them is a designated COVID-19 facility. The sleep quality, depression, eating habits, social bonds, and quality of life were measured using The Insomnia Severity Index (ISI), Depression Anxiety and Stress Scale 21 (DASS-21), Emotional Eater Questionnaire (EEQ), Oslo Social Support Scale (OSSS-3), and the World Health Organization Quality of Life (WHOQOL-BREF), respectively. Results: A total of 200 nurses participated in the study (RR: 13.3%). No statistically significant association was found between designated facility (COVID-19 vs. not COVID-19) or nurses’ characteristics and ISI categories (OR 1.15; 95% CI 0.54, 2.44). Nurses working in COVID-19 facilities had increased odds of having higher EEQ categories by 2.62 times (95% CI 1.18, 5.83). Similarly, no statistically significant associations were found between any of the nurses’ characteristics and OSSS-3 categories. On the other hand, no statistically significant associations were found between any of the nurses’ characteristics and QOL domains except for the gender and social relationships’ domain. Conclusion: Overall, the quality of life of nurses in Qatar is on a positive level whether they are assigned to a COVID-19 facility or not. Although no significant difference was found with regard to the sleep quality, stress, anxiety, depression, and eating habits between nurses in a COVID-19 facility and in a non-COVID-19 facility, special interventions to diminish stressors need to be implemented and maintained.

15 June 2023 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
MAMothana K. Al-Omari
Mothana K. Al-Omari
MEMai Elaarag
Mai Elaarag
ASAlrayyan Private school
Alrayyan Private school
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
AZAyman A. Zarour
Ayman A. Zarour
AAAbdulla A. Al-Ansari
Abdulla A. Al-Ansari
Boronic acids/esters have recently emerged in the field of medicinal and pharmaceutical research due to their exceptional oxophilicity, low toxicity, and unique structure. They are known as potent enzyme inhibitors, cancer therapy capture agents, and can mimic certain types of antibodies to fight infections. They have been designed and developed into drugs, and this approach has emerged in the last 20 years. Five boronic acid drugs have been approved by the FDA and Health Canada, two of which are used to treat cancer, specifically multiple myeloma. The purpose of this review is to investigate boronic acid/ester derivatives as potential pharmaceutical agents as well as the mechanism of action. It will concentrate on six types of cancer: multiple myeloma, prostate cancer, breast cancer, lung cancer, cervical cancer, and colon cancer. Some newly developed boron-containing compounds have already demonstrated highly promising activities, but further investigation is required before final conclusions can be drawn.

21 February 2024 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
Mazhar Al ZoubiMazhar Al Zoubi
Mazhar Al Zoubi
RKRasha Al Kreasha
Rasha Al Kreasha
SASarah Aqel
Sarah Aqel
ASAhmad Saeed
Ahmad Saeed
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
ASAlrayyan Private school
Alrayyan Private school
Metformin is the most prescribed oral hypoglycemic drug and is considered by many health practitioners as the first-line treatment for non-insulin-dependent diabetes mellitus (T2DM). It is used either as a monotherapy or adjuvant to other anti-hyperglycemic agents. Most of its side effects are usually mild and self-limiting. However, several studies have shown an association between the use of metformin and low vitamin B12 levels in diabetic patients. The current review aimed to provide a literature review of the current published reports on the association, the possible mechanisms, and the related individualized risk factors that might lead to this incidence. The most accepted mechanism of the effect of metformin on vitamin B12 level is related to the absorption process where metformin antagonism of the calcium cation and interference with the calcium-dependent IF-vitamin B12 complex binding to the ileal cubilin receptor. In addition, many risk factors have been associated with the impact of metformin on vitamin B12 levels in diabetic patients such as dose and duration where longer durations showed a greater prevalence of developing vitamin B12 deficiency. Male patients showed lower levels of vitamin B12 compared to females. Black race showed a lower prevalence of vitamin B12 deficiency in metformin-treated patients. Moreover, chronic diseases including T2DM, hyperlipidemia, coronary artery disease, polycystic ovary disease (PCOD), obesity, and metformin therapy were significantly associated with increased risk of vitamin B12 deficiency. Graphical abstract Metformin impacts vitamin B12 by (A) inhibiting calcium-dependent IF-B12 binding. (B) Prolonged use raises deficiency risk. (C) Males have lower B12 levels than females. (D) Black individuals show lower deficiency rates. (E) Conditions like T2DM, hyperlipidemia, coronary artery disease, PCOD, obesity, and metformin use heighten deficiency risk.

3 July 2021 in Arab Journal of Urology
Verified
Journal Article
Open access
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
ASAlrayyan Private school
Alrayyan Private school
AYAksam Yassin
Aksam Yassin
MAMustafa Alwani
Mustafa Alwani
OAOmar M. Aboumarzouk
Omar M. Aboumarzouk
AAAbdulla Al Ansari
Abdulla Al Ansari
Objectives: To report the association between testosterone treatment in hypogonadal men with hepatic steatosis, non-alcoholic fatty liver disease and cardiovascular disease (CVD). Methods: A prospective study was conducted to assess the physiological and functional performance of the long-term effects of testosterone undecanoate treatment on hepatic steatosis in 496 hypogonadal men. Two groups were studied, the treatment group (T-group) of 312 patients treated with TU 1000 mg every 12 weeks and followed for 8 years, and an untreated control group (C-group) of 184 patients. We evaluated liver functions and Fatty Liver Index (FLI) according to Mayo Clinic parameters and guidelines. Results: The T-group showed a decrease in the FLI (from a mean [SD] of 83.70 [12.15] to 67.12 [19.21]), bilirubin (from a mean [SD] of 1.69 [4.21] to 1.31 [1.91] mg/dL), triglycerides (from a mean [SD] of 254.87 [92.99] to 213.37 [66.91] mg/dL), and gamma-glutamyl-transferase (from a mean [SD] of 39.45 [11.51] to 29.11 [7.68] U/L) over the duration of the study. Other parameters were also reduced in the T-group such as body mass index (from a mean [SD] of 31.59 [4.51] to 29.50 [3.84] kg/m2) and waist circumference (from a mean [SD] of 107.51 [9.95] to 101.86 [9.28] cm). A total of 25 deaths (7.8%) were recorded in the T-group, among them, 11 (44%) were related to CVD. While in the C-group 28 deaths (15.2%) were recorded and all the reported deaths (100%) were related to CVD. Conclusions: The findings suggest that long-term testosterone therapy in hypogonadal men improves liver function. While, the physiological and functional improvements in the liver may be associated with a decrease in CVD-related mortality. Abbreviations ALT: alanine transaminase; AR: androgen receptor; AST: aspartate transaminase; BMI: body mass index; CVD: cardiovascular disease; FLI: Fatty Liver Index; γ-GT: gamma-glutamyl-transferase; MetS: metabolic syndrome; LDL: low-density lipoprotein; NAFLD: non-alcoholic fatty liver disease; RCT: randomised controlled trial; T2DM: type II diabetes mellitus; TT: total testosterone; TTh: testosterone therapy; TU: testosterone undecanoate; WC: waist circumference

19 February 2025 in Health Science Reports
Verified
Journal Article
Open access
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
ZFZainab E. Fares
Zainab E. Fares
MEMai Elaarag
Mai Elaarag
MOMaha Osman
Maha Osman
ASAlrayyan Private school
Alrayyan Private school
OAOmar M. Aboumarzouk
Omar M. Aboumarzouk
Background and Aims: Artificial intelligence (AI) has become integral to medical research, impacting various aspects such as data analysis, writing assistance, and publishing. This paper explores the multifaceted influence of AI on the process of writing medical research papers, encompassing data analysis, ethical considerations, writing assistance, and publishing efficiency.Methods: The review was conducted following the PRISMA guidelines; a comprehensive search was performed in Scopus, PubMed, EMBASE, and MEDLINE databases for research publications on artificial intelligence in medical research published up to October 2023.Results: AI facilitates the writing process by generating drafts, offering grammar and style suggestions, and enhancing manuscript quality through advanced models like ChatGPT. Ethical concerns regarding content ownership and potential biases in AI‐generated content underscore the need for collaborative efforts among researchers, publishers, and AI creators to establish ethical standards. Moreover, AI significantly influences data analysis in healthcare, optimizing outcomes and patient care, particularly in fields such as obstetrics and gynecology and pharmaceutical research. The application of AI in publishing, ranging from peer review to manuscript quality control and journal matching, underscores its potential to streamline and enhance the entire research and publication process. Overall, while AI presents substantial benefits, ongoing research, and ethical guidelines are essential for its responsible integration into the evolving landscape of medical research and publishing.Conclusion: The integration of AI in medical research has revolutionized efficiency and innovation, impacting data analysis, writing assistance, publishing, and others. While AI tools offer significant benefits, ethical considerations such as biases and content ownership must be addressed. Ongoing research and collaborative efforts are crucial to ensure responsible and transparent AI implementation in the dynamic landscape of medical research and publishing.